Dr Chloe Bloom: key facts
- Kind of voice
- Academic
- Role
- Clinical Associate Professor in Respiratory Epidemiology at the National Heart & Lung Institute, Imperial College London, UK
- Quoted on
- Respiratory (asthma/COPD)
- Press citations held
- 3
- Most recently quoted
- 29 Sept 2026
“Obesity is strongly associated with asthma. People with asthma who also have obesity and/or type 2 diabetes tend to have more symptoms and a higher risk of asthma attacks.”
What Dr Chloe Bloom has said
“GLP-1 receptor agonists are widely used to treat type 2 diabetes and obesity. Previous research suggests that they may have anti-inflammatory effects and may improve lung-related outcomes. However, asthma and COPD outcomes have not been included as outcomes in GLP-1 drug trials.”
Clinical Associate Professor in Respiratory Epidemiology at the National Heart & Lung Institute, Imperial College London, UK · Respiratory (asthma/COPD) · 29 Sept 2026 · Ozempic and Wegovy linked to nearly 40% fewer asthma attacks ↗
“GLP-1 receptor agonists are widely used to treat type 2 diabetes and obesity. Previous research suggests that they may have anti-inflammatory effects and may improve lung-related outcomes. However, asthma and COPD outcomes have not been included as outcomes in GLP-1 drug trials.”
Clinical associate professor in respiratory epidemiology at the National Heart & Lung Institute at Imperial College London · Respiratory (asthma/COPD) · 29 Sept 2026 · Semaglutide linked to 40% reduction in asthma attacks ↗
Where Dr Chloe Bloom has been quoted
- GLP-1s May Reduce Asthma Attack Frequency, Study Suggestseverydayhealth.com · 29 Sept 2026
- Ozempic and Wegovy linked to nearly 40% fewer asthma attackssciencedaily.com · 29 Sept 2026
- Semaglutide linked to 40% reduction in asthma attacksthepharmacist.co.uk · 29 Sept 2026
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 29 Sept 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.